alzheimer’s disease
-
Covid is Still With Us. What Does That Mean for Your Brain?
We may not fully understand the link between Covid-19 and Alzheimer’s, but we already have the scientific research and tools to address people’s fears, support their cognitive health journey, and reverse the increase of Alzheimer’s.
-
Eli Lilly Strengthens the Case for Going Early in Alzheimer’s Treatment
Alzheimer’s disease patients in the earliest stages of their disease benefited the most from Eli Lilly drug donanemab, which is expected to receive an FDA decision by the end of 2023. Full results from the drug’s pivotal study were presented during the during the Alzheimer’s Association International Conference.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
MedCity Influencers, Devices & Diagnostics
3 Things Health Systems Must Do Today to Prepare for New Alzheimer’s Treatments
As more life-extending medications come on the market, health systems have a responsibility to make meaningful changes in how they screen and reach older adults. Earlier detection could mean millions of individuals enjoy longer lives of good cognitive health.
-
Eisai Alzheimer’s Drug Wins Full FDA Approval, But With Sterner Safety Alert
Six months after Esai Alzheimer’s disease drug Leqembi received accelerated FDA approval, the agency has awarded the drug full approval. While the agency’s regulatory decision sets precedent for other Alzheimer’s drugs, it also flags serious safety risks.
-
CMS Will Cover Approved Alzheimer’s Drugs, But It Still Wants More Evidence
Medicare will cover Alzheimer’s disease drugs granted traditional FDA approval, CMS announced. But the decision keeps the spirit of an earlier coverage determination, which called for the gathering of more evidence about the safety and efficacy of these therapies.
-
FDA Approves First Drug for Treating Agitation in Alzheimer’s Patients
Rexulti, a drug for schizophrenia and depression, now has an additional approval for treating agitation in Alzheimer’s disease patients. The FDA decision makes the Otsuka Pharmaceutical and Lundbeck product the first drug approved for this indication.
-
Eli Lilly Alzheimer’s Drug Meets Phase 3 Goals, Teeing Up Plans for FDA Filing
Patients treated with Eli Lilly Alzheimer’s disease drug donanemab showed a 35% slowing in decline compared to those given a placebo. Based on the Phase 3 results, Lilly said it would seek FDA approval for the drug by the end of June.
-
Startup Therini Bio Lands $36M to Take Blood Protein R&D to Alzheimer’s & More
Merck, Sanofi, and Eli Lilly joined the Series A financing of Therini Bio, a startup developing a drug that selectively targets fibrin as a way of reducing disease-driving inflammation in neurodegeneration and eye disorders such as diabetic macular edema. Therini is preparing to advance its lead program to clinical testing.
-
MedCity Influencers, BioPharma
A New Alzheimer’s Drug is Finally Here – Our Healthcare System is Far from Ready
The new year always brings hope, but this January that hope was palpable for the […]
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Devices & Diagnostics, BioPharma
Neuro Startup Cognito Corrals $73M as Alzheimer’s Device Commences Key Test
Alzheimer’s disease research at MIT spawned Cognito Therapeutics, a startup whose medical device uses light and sound to modulate electrical activity that supports brain health. The company’s Series B financing will support a Phase 3 test of its technology in patients with mild-to-moderate disease.
-
Eisai Alzheimer’s Drug Gets FDA Decision Date; Advisory Meeting Is Planned
Leqembi, the Eisai Alzheimer’s disease drug awarded accelerated FDA approval in January, could receive a decision on full approval in early July. But in setting the target date for a regulatory decision, the agency also said it plans to convene an advisory committee meeting to discuss the drug.
-
FDA Rejects Eli Lilly Alzheimer’s Drug, Asks for More Data From Ongoing Study
Eli Lilly’s accelerated approval application for its Alzheimer’s disease drug has fallen short. The company said the FDA is asking for data from more patients—results that must come from a larger study that’s underway but won’t report data until later this year.
-
Ending Involuntary Commitments Would Shift Burden of Montana’s Dementia Care to Strapped Communities
A budget estimate attached to proposed legislation in Montana raises questions about whether the state’s cash-strapped communities will have the capacity to care for patients with Alzheimer’s disease, other types of dementia or traumatic brain injuries by July 2025, when involuntary commitments would cease under the plan.
-
FDA Approval of Eisai Alzheimer’s Drug Bears Imprint of Aduhelm Review
Eisai Alzheimer’s disease drug Leqembi is now approved for the treatment of patients with an early form of the memory-robbing disease. In granting the antibody accelerated approval, the FDA employed reasoning that was the also basis for the controversial speedy regulatory nod for Biogen’s drug, Aduhelm.
-
This Startup is Proving that Family Caregivers Have the Power to Lower Admissions and Reduce Costs
Reducing hospitalizations for frail elderly members is a major challenge for Medicare Advantage payers and providers. The key to avoiding any hospitalization is to detect and address a change in condition before it worsens. Ceresti Co-founder and CEO Dirk Soenksen talks about how his company is addressing these needs.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
